Currently Enrolling Clinical Trials

Retina-Vitreous Associates Medical Group has participated in clinical research for over 15 years and is committed to the development of novel diagnostic and therapeutic modalities for retinal disease. All of our physicians participate in clinical trials, giving patients unique and easy access to the latest developments in treatments of vitreoretinal diseases. We are committed to bettering the quality, efficacy, and ease of treatment for our patients. Transportation may be provided.

**Retinitis Pigmentosa (RP)**
A genetic condition causing progressive vision loss. Night blindness usually occurs first, followed by peripheral, central, and color vision loss.

We are investigating implantation of human stem cell-derived retinal progenitor cells that may offer long-term visual benefits to patients who otherwise have no other treatments available.

**Macular Degeneration (Age-related/AMD) Dry & Wet**
The leading cause of vision loss in America, AMD is progressive disorder affecting the central vision in patients 50 years or older.

We provide trials for both early and end stage **Dry** and **Wet** AMD using in-office as well as surgical treatments. We are now investigating treatments with Stem Cells, Photomodulation, oral medications, subcutaneous injections, and intravitreal injections.

**Diabetic Retinopathy**
Patients with type 1 and type 2 diabetes can suffer from damage to the blood vessels in the retina, causing mild to severe vision loss and potentially blindness.

Currently under investigation are trials for Proliferative Diabetic Retinopathy with Macular Ischemia.

**Diabetic Macular Edema (DME)**
An accumulation of swelling in the central retina that causes vision loss in diabetic patients. This is a component of diabetic retinopathy.

Our trials look for novel treatments for diabetic macular edema and in combination with current gold-standard treatment.

Trials available for both **Treatment Naïve** and **Previously Treated** patients.

**Retinal Vein Occlusion (CRVO and BRVO)**
Commonly referred to as a “stroke in the eye”, a blood clot in the retinal blood vessels can cause vision loss and secondary glaucoma.

We are investigating multiple novel treatments to improve outcomes and decrease the number of necessary visits and procedures.

**Uveitis: Anterior, Intermediate, Posterior, and Pan-Uveitis**
A broad term for inflammation of the eye, it can be classified based on the parts of the eye that are affected.

We offer a spectrum of trials: subcutaneous injections, intravitreal injections, and oral medication for various types of uveitis.

**Stargardt Disease**
A rare genetic macular condition (ABCA4 mutation) for which we are now offering a Phase 3 treatment trial.

**Macular Telangiectasia/Idiopathic Juxtafoveal Retinal Telangiectasis**
A rare bilateral macular disease of unknown cause that usually causes mild to moderate vision loss. We are investigating an advanced technology macrocellular implant.